[Diagnostic and therapeutic recommendations for sexually transmitted diseases: Genital herpes].

Recommandations diagnostiques et thérapeutiques pour les maladies sexuellement transmissibles : herpès génital au cours de la grossesse.

Journal

Annales de dermatologie et de venereologie
ISSN: 0151-9638
Titre abrégé: Ann Dermatol Venereol
Pays: France
ID NLM: 7702013

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 28 11 2017
accepted: 13 07 2018
pubmed: 28 10 2018
medline: 31 7 2019
entrez: 28 10 2018
Statut: ppublish

Résumé

TREATMENT OF THE INITIAL INFECTION OR FIRST CLINICAL EPISODE OF GENITAL HERPES: An initial infection or first clinical episode of genital herpes is treated with oral aciclovir 200mg×5/d for 5 to 10 days depending on clinical status. The recommended dosage for valaciclovir is 1g×2/d and treatment duration is identical to that for aciclovir. TREATMENT OF HERPES RECURRING DURING PREGNANCY: There are no studies of the efficacy of antiviral therapy on the symptoms of genital recurring during pregnancy. However, initial anti-viral treatment using aciclovir or valaciclovir may be given where warranted by symptoms (i.e. duration and severity of symptoms). Valaciclovir may be used instead (equivalent efficacy but better safety data for aciclovir). Valaciclovir may be given at a dosage of 1×500mg b.i.d. p.o. for 5 days. PROPHYLACTIC ANTI-VIRAL TREATMENT DURING PREGNANCY: In female patients presenting an initial infection or infection recurring during pregnancy, although there is no demonstrated benefit for prophylactic treatment in reducing the risk of neonatal herpes, anti-viral prophylaxis is recommended after 36 WA (weeks' amenorrhoea) to limit the need for Caesarean section due to herpetic lesions. The recommended antivirals are aciclovir at a dosage of 400mg t.i.d p.o. or valaciclovir at a dosage of 500mg b.i.d. p.o. until delivery.

Identifiants

pubmed: 30366717
pii: S0151-9638(18)30717-8
doi: 10.1016/j.annder.2018.07.029
pii:
doi:

Substances chimiques

Antiviral Agents 0
Valacyclovir MZ1IW7Q79D
Acyclovir X4HES1O11F

Types de publication

Journal Article Review

Langues

fre

Pagination

31-36

Informations de copyright

Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Auteurs

B Milpied (B)

Service de dermatologie, hôpital Saint-André, CHU, 1, rue Jean-Burguet, 33000 Bordeaux, France.

M Janier (M)

Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France.

J Timsit (J)

Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France.

N Spenatto (N)

Pôle santé publique et médecine sociale, service de dermatologie et médecine sociale, hôpital La-Grave, place Lange, TSA 60033, 31059 Toulouse cedex 9, France.

E Caumes (E)

Service des maladies infectieuses et tropicales, hôpital Pitié-Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris, France.

O Chosidow (O)

Service de dermatologie, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France. Electronic address: olivier.chosidow@aphp.fr.

L Sentilhes (L)

Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.

M-V Senat (MV)

Marie-Victoire Senat, service de gynécologie-obstétrique, Paris-Sud-université Paris-Saclay, hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH